Cerus Corporation (CERS) Signs Five-Year Agreement With Belgian Red Cross Flanders For The INTERCEPT Blood System For Platelets
5/29/2014 9:07:15 AM
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the Belgian Red Cross Flanders (RC-F) has signed a five-year agreement to purchase the INTERCEPT Blood System for platelets. RC-F is one of two major Red Cross blood services in Belgium, and supplies approximately 37,000 platelet components to the northern, or Flemish, region of Belgium.
Help employers find you! Check out all the jobs and post your resume.
comments powered by